Aurora Capital LLC has completed offerings for life sciences companies for over a decade; deals have included:

DOV Pharmaceutical, Inc. PIPE
Aurora Capital sole placement agent

DOV Pharmaceutical, Inc. Series D Convertible Preferred
Aurora Capital was a selected dealer on the transaction with a bulge bracket firm

DOV Pharmaceutical, Inc. Series C Convertible Preferred
Aurora Capital sole placement agent

DOV Pharmaceutical, Inc. and Elan Corporation Series B Equity and Debt Financing and Joint Venture
Aurora Capital sole placement agent

Neurocrine Biosciences and DOV Pharmaceutical, Inc. Sub-License, Equity Financing Series A Convertible Preferred
Aurora Capital acted as advisor to DOV

InKine Private Equity Placement exempt from registration
Aurora Capital lead co-placement agent

Encysive Pharmaceuticals (formerly, Texas Biotechnology Corp.) Private Equity Placement exempt from registration
Aurora Capital co-exclusive placement agent

RegenRx Private Equity Placement exempt from registration
Aurora Capital acted as sole placement agency in company offering

Boston Life Sciences Private Equity Placement exempt from registration
Aurora Capital assisted another investment bank in a private placement

Cambridge Heart Private Equity Placement exempt from registration
Aurora Capital acted as selected dealer

Structural Bioinformatics Private Placement exempt from registration
(Series A and B)
Aurora Capital acted as exclusive placement agent

ChromaXome Corp Private Placement exempt from registration
Aurora Capital acted as exclusive placement agent

Vector Therapeutics Private Equity Placements exempt from registration (Series A and B)
Aurora Capital acted as exclusive placement agent

Predict Inc. Private Equity Placement exempt from registration
Aurora Capital acted as sole placement agent
Powered by